Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11279510 | 0.89 | CHRM3 (0.42) | CYP2C9CHRM3CYP1A2L3MBTL1HTT | |
| SCHEMBL2075002 | 0.88 | PTPN1 (0.42) | CYP2C9CHRM3L3MBTL1CYP2D6HIF1A | |
| SCHEMBL73485 | 0.87 | CHRM3 (0.41) | CYP2C9CHRM3CYP1A2L3MBTL1HTT | |
| Bromomethane SCHEMBL6308629 | 0.83 | MAPT (0.42) | CYP2C9CHRM3L3MBTL1CYP2D6HIF1A | |
| SCHEMBL807675 | 0.83 | PTPN1 (0.44) | CHRM3L3MBTL1MAPTPTPN1CES2 | |
| SCHEMBL71406 | 0.82 | KCNN4 (0.50) | CHRM3L3MBTL1HTTLMNAHIF1A | |
| Benzylic Acid SCHEMBL4414459 | 0.80 | CYP2C9 (0.52) | CYP2C9CYP1A2L3MBTL1HTTLMNA | |
| SCHEMBL30230256 | 0.78 | CES1 (0.44) | MAPTPTPN1CYP2C19CES2CES1 | |
| Benzylic Acid SCHEMBL7066 | 0.77 | CYP2C9 (0.74) | CYP2C9CHRM3CYP1A2L3MBTL1HTT | |
| SCHEMBL71754 | 0.76 | MAPT (0.42) | CHRM3L3MBTL1MAPTPTPN1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120321565-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 17ALPHA-FURANYLESTERS OF 17BETA-CARBOTHIATE ANDROSTANES WITH A MUSCARINIC RECEPTOR ANTAGONIST | GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED (GB) | 2012-12-20 | — | — | US | claimed |
| US-20080214600-A1 | Quaternized Quinuclidine Esters | ALMIRALL PRODESFARMA, SA (ES) | 2008-09-04 | — | — | US | claimed |
| EP-1725552-B1 | NEW QUATERNIZED QUINUCLIDINE ESTERS | ALMIRALL LAB (ES) | 2008-06-25 | — | — | EP | claimed |
| EP-1725552-A1 | NEW QUATERNIZED QUINUCLIDINE ESTERS | Almirall Prodesfarma, S.A. (ES) | 2006-11-29 | — | — | EP | claimed |
| US-20060002861-A1 | Pharmaceutical compositions comprising 17alpha-furanylesters of 17beta-carbothiate androstanes with a muscarinic receptor antagonist | GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED (GB) | 2006-01-05 | — | — | US | claimed |
| WO-2005090342-A1 | NEW QUATERNIZED QUINUCLIDINE ESTERS | ALMIRALL PRODESFARMA, SA (ES) | 2005-09-29 | — | — | WO | claimed |
| EP-1471919-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 17ALPHA-FURANYLESTERS OF 17BETA-CARBOTHIOATE ANDROSTANES WITH A MUSCARINIC RECEPTOR ANTAGONIST | GLAXO GROUP LTD (GB) | 2005-08-10 | — | — | EP | claimed |
| EP-1471919-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 17ALPHA-FURANYLESTERS OF 17BETA-CARBOTHIOATE ANDROSTANES WITH A MUSCARINIC RECEPTOR ANTAGONIST | GLAXO GROUP LIMITED (GB) | 2004-11-03 | — | — | EP | claimed |
| WO-2003066063-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 17ALPHA-FURANYLESTERS OF 17BETA-CARBOTHIOATE ANDROSTANES WITH A MUSCARINIC RECEPTOR ANTAGONIST | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | claimed |
| US-10588895-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2020-03-17 | — | — | US | disclosed |
| US-20190183867-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL SA (ES) | 2019-06-20 | — | — | US | disclosed |
| US-10034867-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2018-07-31 | — | — | US | disclosed |
| US-20170319557-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA, S.A. (ES) | 2017-11-09 | — | — | US | disclosed |
| US-9687478-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2017-06-27 | — | — | US | disclosed |
| US-6750226-B2 | FOR MANUFACTURE OF MEDICAMENT FOR USE IN THERAPY OF RESPIRATORY, URINARY OR GASTROINTESTINAL DISEASE | ALMIRALL-PRODESFARMA, S.A. (ES) | 2004-06-15 | — | — | US | disclosed |
| WO-2003066063-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 17ALPHA-FURANYLESTERS OF 17BETA-CARBOTHIOATE ANDROSTANES WITH A MUSCARINIC RECEPTOR ANTAGONIST | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | disclosed |
| EP-1200431-B1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTORS LIGANDS | ALMIRALL PRODESFARMA AG (CH) | 2003-03-26 | — | — | EP | disclosed |
| US-20030055080-A1 | For manufacture of medicament for use in therapy of respiratory, urinary or gastrointestinal disease | ALMIRALL, S.A. (ES) | 2003-03-20 | — | — | US | disclosed |
| EP-1200431-A2 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR LIGANDS | Almirall Prodesfarma, S.A. (ES) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001004118-A2 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR LIGANDS | ALMIRALL PRODESFARMA S.A. (ES) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214600-A1 | Quaternized Quinuclidine Esters | NQO2, QPCT, QARS1 | CYP2C9 83/4885CHRM3 222/4885CYP1A2 133/4885 |
| US-10034867-B2 | Quinuclidine derivatives and medicinal compositions containing the same | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM3, OPRD1 | CYP2C9 1053/4885CHRM3 2/4885CYP1A2 201/4885 |
| US-20190183867-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRNB1, ARRB1 | CYP2C9 2304/4885CHRM3 1/4885CYP1A2 306/4885 |
| US-20030055080-A1 | For manufacture of medicament for use in therapy of respiratory, urinary or gastrointestinal disease | NR1H4, CHRM3, CHRM4 | CYP2C9 810/4885CHRM3 2/4885CYP1A2 924/4885 |
| US-20060002861-A1 | Pharmaceutical compositions comprising 17alpha-furanylesters of 17beta-carbothiate androstanes with a muscarinic receptor antagonist | CYP17A1, HSD17B7, NR5A1 | CYP2C9 254/4885CHRM3 6/4885CYP1A2 138/4885 |
| US-20120321565-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 17ALPHA-FURANYLESTERS OF 17BETA-CARBOTHIATE ANDROSTANES WITH A MUSCARINIC RECEPTOR ANTAGONIST | CYP17A1, HSD17B7, NR5A1 | CYP2C9 254/4885CHRM3 6/4885CYP1A2 138/4885 |
| US-20170319557-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM3, OPRD1 | CYP2C9 1077/4885CHRM3 2/4885CYP1A2 218/4885 |
| US-10588895-B2 | Quinuclidine derivatives and medicinal compositions containing the same | CHRM3, QDPR, CHRM2 | CYP2C9 1525/4885CHRM3 1/4885CYP1A2 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.